PharmaResources (Shanghai) Co., Ltd. (SHE:301230)
China · Delayed Price · Currency is CNY 46.71
+0.52 (1.13%)
At close: Feb 12, 2026
SHE:301230 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 652.95 | 529.95 | 480.48 | 472.12 | 446.44 | 278.5 |
Other Revenue | 14.52 | 14.52 | 9.24 | 6.76 | 1.77 | 4.49 |
| 667.47 | 544.47 | 489.72 | 478.88 | 448.21 | 282.99 | |
Revenue Growth (YoY) | 29.88% | 11.18% | 2.26% | 6.84% | 58.38% | 15.41% |
Cost of Revenue | 485.59 | 413.89 | 350.61 | 304.46 | 278 | 166.56 |
Gross Profit | 181.88 | 130.58 | 139.11 | 174.42 | 170.22 | 116.43 |
Selling, General & Admin | 110.46 | 89.18 | 73.59 | 80.17 | 61.87 | 43.98 |
Research & Development | 40.15 | 47.26 | 37.34 | 32.65 | 17.14 | 11.67 |
Other Operating Expenses | 5.38 | 1.76 | 1.24 | 1.66 | 1.77 | 0.91 |
Operating Expenses | 158.74 | 139.48 | 112.46 | 114.17 | 83.24 | 55.81 |
Operating Income | 23.14 | -8.9 | 26.64 | 60.25 | 86.98 | 60.62 |
Interest Expense | -8.54 | -9.28 | -5.46 | -4.79 | -2.53 | -1.22 |
Interest & Investment Income | 1.86 | 6.57 | 6.16 | 3.49 | 2.42 | 2.01 |
Currency Exchange Gain (Loss) | 5.37 | 5.37 | 0.7 | 9.44 | -2.56 | -9.16 |
Other Non Operating Income (Expenses) | -0.85 | -0.2 | -0.18 | -0.16 | -0.14 | -0.21 |
EBT Excluding Unusual Items | 20.97 | -6.44 | 27.86 | 68.23 | 84.17 | 52.05 |
Gain (Loss) on Sale of Investments | 6.17 | 4.97 | 5.58 | -0.1 | 0.4 | - |
Gain (Loss) on Sale of Assets | -0.21 | - | 0.01 | -0.07 | 0.05 | - |
Asset Writedown | -5.62 | -0.29 | -0.71 | - | -0.49 | -0.3 |
Other Unusual Items | 7.59 | 5.29 | 4.02 | 4.86 | 2.1 | 3.46 |
Pretax Income | 28.9 | 3.54 | 36.76 | 72.92 | 86.23 | 55.22 |
Income Tax Expense | -7.69 | -13.55 | -0.86 | 5.75 | 12.66 | 6.52 |
Net Income | 36.59 | 17.08 | 37.62 | 67.18 | 73.58 | 48.69 |
Net Income to Common | 36.59 | 17.08 | 37.62 | 67.18 | 73.58 | 48.69 |
Net Income Growth | 428.07% | -54.59% | -44.00% | -8.70% | 51.11% | 3.04% |
Shares Outstanding (Basic) | 143 | 142 | 139 | 111 | 105 | 103 |
Shares Outstanding (Diluted) | 143 | 142 | 139 | 111 | 105 | 103 |
Shares Change (YoY) | 3.34% | 2.17% | 26.04% | 5.66% | 1.58% | 1.86% |
EPS (Basic) | 0.26 | 0.12 | 0.27 | 0.61 | 0.70 | 0.47 |
EPS (Diluted) | 0.26 | 0.12 | 0.27 | 0.61 | 0.70 | 0.47 |
EPS Growth | 411.03% | -55.56% | -55.57% | -13.59% | 48.85% | 1.18% |
Free Cash Flow | 73.58 | -28.54 | -227.41 | -24.67 | 13.01 | 20.94 |
Free Cash Flow Per Share | 0.51 | -0.20 | -1.63 | -0.22 | 0.12 | 0.20 |
Dividend Per Share | 0.500 | 0.430 | 0.254 | 0.275 | - | - |
Dividend Growth | 41.32% | 69.42% | -7.61% | - | - | - |
Gross Margin | 27.25% | 23.98% | 28.41% | 36.42% | 37.98% | 41.14% |
Operating Margin | 3.47% | -1.63% | 5.44% | 12.58% | 19.41% | 21.42% |
Profit Margin | 5.48% | 3.14% | 7.68% | 14.03% | 16.42% | 17.21% |
Free Cash Flow Margin | 11.02% | -5.24% | -46.44% | -5.15% | 2.90% | 7.40% |
EBITDA | 52.89 | 17 | 47.41 | 76.6 | 99.57 | 72.38 |
EBITDA Margin | 7.92% | 3.12% | 9.68% | 16.00% | 22.22% | 25.58% |
D&A For EBITDA | 29.75 | 25.9 | 20.77 | 16.35 | 12.59 | 11.76 |
EBIT | 23.14 | -8.9 | 26.64 | 60.25 | 86.98 | 60.62 |
EBIT Margin | 3.47% | -1.63% | 5.44% | 12.58% | 19.41% | 21.42% |
Effective Tax Rate | - | - | - | 7.88% | 14.68% | 11.82% |
Revenue as Reported | 667.47 | 544.47 | 489.72 | 478.88 | 448.21 | 282.99 |
Advertising Expenses | - | 0.21 | 0.11 | 0.43 | 0.03 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.